

Cover Story
More than a decade ago, Glenn Begley and Lee Ellis published a paper with astounding findings: of 53 “landmark” studies, only six, or 11%, were reproducible, even with the same reagents and the same protocols—and even, sometimes, in the same laboratory—as the original study.
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for February 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval - City of Hope’s leadership in lung cancer: Precision, innovation, and a vision for cure
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
















